Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2020 April EHA 2019 Brentuximab vedotin + AVD provides durable benefit in Hodgkin’s lymphoma patients Read more
2020 April EHA 2019 Acalabrutinib delays disease progression in patients with relapsed/refractory CLL Read more
2020 April EHA 2019 Voxelotor induces robust improvements in anemia in patients with sickle cell disease Read more
Top
